<br>        Inclusion Criteria:<br><br>          -  Healthy male subjects according to the assessment of the investigator, based on a<br>             complete medical history including a physical examination, vital signs (Blood Pressure<br>             [BP], Pulse Rate [PR]), 12-lead Electrocardiogram [ECG], and clinical laboratory tests<br><br>          -  Age of 18 to 45 years (incl.)<br><br>          -  Body Mass Index [BMI] of 18.5 to 29.9 kg/m2 (incl.)<br><br>          -  Signed and dated written informed consent prior to admission to the study in<br>             accordance with Good Clinical Practice[ GCP] and local legislation<br><br>        Exclusion Criteria:<br><br>          -  Any finding in the medical examination (including Blood Pressure [BP], Pulse Rate [PR]<br>             or Electrocardiogram [ECG]) is deviating from normal and judged as clinically relevant<br>             by the investigator<br><br>          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,<br>             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the<br>             range of 50 to 90 bpm<br><br>          -  Any laboratory value outside the reference range that the investigator considers to be<br>             of clinical relevance<br><br>          -  Any evidence of a concomitant disease judged as clinically relevant by the<br>             investigator<br><br>          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,<br>             immunological or hormonal disorders<br><br>          -  Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with<br>             the pharmacokinetics of the trial medication (except appendectomy and simple hernia<br>             repair)<br><br>          -  Diseases of the central nervous system (including but not limited to any kind of<br>             seizures or stroke), and other relevant neurological or psychiatric disorders<br><br>          -  History of relevant orthostatic hypotension, fainting spells, or blackouts<br><br>          -  Chronic or relevant acute infections<br><br>          -  History of relevant allergy or hypersensitivity (including allergy to the trial<br>             medication or its excipients)<br><br>          -  Use of drugs within 30 days prior to administration of trial medication if that might<br>             reasonably influence the results of the trial (incl. QT/QTc interval prolongation)<br><br>          -  Participation in another trial where an investigational drug has been administered<br>             within 60 days prior to planned administration of trial medication, or current<br>             participation in another trial involving administration of investigational drug<br><br>          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)<br><br>          -  Inability to refrain from smoking on specified trial days<br><br>          -  Alcohol abuse (consumption of more than 30 g per day)<br><br>          -  Drug abuse or positive drug screening<br><br>          -  Blood donation of more than 100 mL within 30 days prior to administration of trial<br>             medication or intended donation during the trial<br><br>          -  Intention to perform excessive physical activities within one week prior to<br>             administration of trial medication or during the trial<br><br>          -  Inability to comply with dietary regimen of trial site<br><br>          -  A marked baseline prolongation of QT/QTc interval such as QTc intervals that are<br>             repeatedly greater than 450 ms or any other relevant ECG finding at screening<br><br>          -  A history of additional risk factors for Torsades de Pointes (such as heart failure,<br>             hypokalemia, or family history of Long QT Syndrome)<br><br>          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,<br>             because considered not able to understand and comply with study requirements, or has a<br>             condition that would not allow safe participation in the study<br><br>        In addition, the following trial-specific exclusion criteria apply:<br><br>          -  Male subjects with female partner of childbearing potential who are unwilling to use<br>             male contraception (condom or sexual abstinence) from the first administration of<br>             trial medication until 30 days after last administration of trial medication<br><br>          -  Current or history of relevant kidney, urinary tract diseases or abnormalities (e.g.<br>             nephrolithiasis, hydronephrosis, acute or chronic nephritis, renal injury, renal<br>             failure)<br><br>          -  Estimated glomerular filtration rate according to CKD-EPI formula < 90 mL/min at<br>             screening<br><br>          -  Within 10 days prior to administration of trial medication, use of any drug that could<br>             reasonably inhibit platelet aggregation or coagulation (e.g., acetylsalicylic acid)<br><br>          -  Further exclusion criteria apply<br>